HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT TO PREVENT CIRRHOSIS (HALT-C)
丙型肝炎抗病毒长期治疗以预防肝硬化 (HALT-C)
基本信息
- 批准号:7719421
- 负责人:
- 金额:$ 1.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-01 至 2008-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAffectAntiviral AgentsBloodBlood specimenChronic Hepatitis CCirrhosisClinic VisitsCoinComputer Retrieval of Information on Scientific Projects DatabaseEnrollmentEsophagusFundingGrantHemorrhageHepatitisHepatitis CInjection of therapeutic agentInstitutionInterferonsMaintenanceMaintenance TherapyMalignant neoplasm of liverPatientsPharmaceutical PreparationsPhaseProceduresQuality of lifeQuestionnairesRecording of previous eventsResearchResearch PersonnelResourcesRibavirinRiskScreening procedureSourceStandards of Weights and MeasuresStomachStreamUnited StatesUnited States Food and Drug AdministrationUnited States National Institutes of HealthVaricosityVeinsViralVisitWeekfollow-upliver biopsyprevent
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Hepatitis C affects about 4 million people in the United States and leads to cirrhosis and liver cancer after many years, in some patients. Treatment with interferon, alone or in combination with a second anti-viral agent ribavirin has been approved by the Food and Drug Administration and is now considered standard therapy for chronic hepatitis C. A slow release form of interferon, called PEG-interferon, remains in the blood stream for one week and gives better results than interferon alone, with fewer injections required. The present study is aimed at patients who have received previous treatment and failed to clear hepatitis C. Patients who meet entry criteria, and are enrolled in the trial, will first be treated with the combination of PEG Interferon plus ribavirin. Responders to this treatment will be given a full one year of therapy. Nonresponders, after 24 weeks of the combination treatment, will be entered into the study of maintenance therapy. Nonresponders will be evenly assigned (by a procedure similar to the toss of a coin) to either maintenance with PEG Interferon (treatment) or no treatment (observation). Follow-up will be identical for the treatment and observation groups and will require 3-monthly visits for 3 1/2 years with 6 months follow-up. Each visit will include history, exam, quality-of-life questionnaire, and blood drawing. Liver biopsies will be performed at two and four years following start of the initial phase. Some patients will undergo endoscopic examination of the esophagus and stomach for varices, large veins at risk for bleed. Risks encountered may include side effects of study medications, that involved in obtaining blood samples, and that of liver biopsy at year 2 and at end of study. Patients will be required to attend two screening visits, plus clinic visits at routine intervals over the entire course of the study.
这个子项目是众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gregory Thomas Everson其他文献
Gregory Thomas Everson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gregory Thomas Everson', 18)}}的其他基金
Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL)
成人至成人活体肝移植队列研究 (A2ALL)
- 批准号:
8015117 - 财政年份:2010
- 资助金额:
$ 1.78万 - 项目类别:
A2ALL LADR PROTOCOL:PRE-TRNSPLNT TRTMNT TO PRVNT RCURRNCE OF HEPC AFT LVR TRNSPL
A2ALL LADR 协议:PRE-TRNSPLNT TRTMNT 到 HEPC AFT LVR TRNSPL 的 PRVNT 复发
- 批准号:
7719478 - 财政年份:2008
- 资助金额:
$ 1.78万 - 项目类别:
QUANTITATIVE ASSESSMENT OF HEPATIC FUNCTION IN CHRONIC HCV (QLFT)
慢性丙型肝炎肝功能的定量评估 (QLFT)
- 批准号:
7719422 - 财政年份:2008
- 资助金额:
$ 1.78万 - 项目类别:
RESTORATION OF HEPATIC FUNCTION IN LIVING LIVER DONORS (ANCILLARY STUDY OF A2ALL
活体肝捐献者肝功能的恢复(A2ALL 的辅助研究
- 批准号:
7719472 - 财政年份:2008
- 资助金额:
$ 1.78万 - 项目类别:
QUANTITATIVE ASSESSMENT OF HEPATIC FUNCTION IN CHRONIC HCV (QLFT)
慢性丙型肝炎肝功能的定量评估 (QLFT)
- 批准号:
7604372 - 财政年份:2007
- 资助金额:
$ 1.78万 - 项目类别:
RESTORATION OF HEPATIC FUNCTION IN LIVING LIVER DONORS (ANCILLARY STUDY OF A2ALL
活体肝捐献者肝功能的恢复(A2ALL 的辅助研究
- 批准号:
7604422 - 财政年份:2007
- 资助金额:
$ 1.78万 - 项目类别:
A2ALL LADR PROTOCOL:PRE-TRNSPLNT TRTMNT TO PRVNT RCURRNCE OF HEPC AFT LVR TRNSPL
A2ALL LADR 协议:PRE-TRNSPLNT TRTMNT 到 HEPC AFT LVR TRNSPL 的 PRVNT 复发
- 批准号:
7604428 - 财政年份:2007
- 资助金额:
$ 1.78万 - 项目类别:
HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT TO PREVENT CIRRHOSIS (HALT-C)
丙型肝炎抗病毒长期治疗以预防肝硬化 (HALT-C)
- 批准号:
7604371 - 财政年份:2007
- 资助金额:
$ 1.78万 - 项目类别:
A2ALL LADR PROTOCOL:PRE-TRNSPLNT TRTMNT TO PRVNT RCURRNCE OF HEPC AFT LVR TRNSPL
A2ALL LADR 协议:PRE-TRNSPLNT TRTMNT 到 HEPC AFT LVR TRNSPL 的 PRVNT 复发
- 批准号:
7377842 - 财政年份:2006
- 资助金额:
$ 1.78万 - 项目类别:
HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT TO PREVENT CIRRHOSIS (HALT-C)
丙型肝炎抗病毒长期治疗以预防肝硬化 (HALT-C)
- 批准号:
7377765 - 财政年份:2006
- 资助金额:
$ 1.78万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 1.78万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 1.78万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 1.78万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 1.78万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 1.78万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 1.78万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 1.78万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 1.78万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 1.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 1.78万 - 项目类别:
Studentship